Tirzepatide 30mg

What is Tirzepatid?

Tirzepatid is a GIP/GLP-1 dual receptor agonist that improves glycemic control in adults with type 2 metabolism and is also indicated for chronic weight management in adults who are obese or overweight and have weight-related complications.

Tirzepatid Structure

Source: PubChem

Sequence: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Molecular Formula: C225H348N48O68

Molecular Weight: 4813 g/mol

CAS Number: 2023788-19-2

PubChem CID: 163285897

Synonyms: Zepbound; Mounjaro

Tirzepatid Research

What is the research background of Tirzepatid?

The research background of Tirzepatid primarily stems from the exploration of metabolism treatment drugs and the demand for weight management drugs. Traditional metabolism treatment drugs have limitations, while GLP-1 receptor agonists demonstrate significant efficacy in improving blood glucose control, prompting researchers to develop more effective drugs of the same class. As a GIP/GLP-1 dual receptor agonist, Tirzepatid can better regulate blood glucose levels. The global increase in overweight and obese populations has made weight control an urgent clinical need. GLP-1 receptor agonists have weight-reducing effects, making them a target for weight loss. Tirzepatid has gained attention due to its favorable weight-loss outcomes.

What is the mechanism of action of Tirzepatid?

Dual receptor agonist action:

Tirzepatid is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist [1,2](Wong E, 2023; Kumar D, 2022). GLP-1 and GIP are both incretin hormones produced in the intestine, playing a crucial role in maintaining glucose homeostasis. Tirzepatid exerts a synergistic effect by simultaneously activating GLP-1 and GIP receptors, thereby regulating blood glucose levels.

Regulation of insulin and glucagon secretion:

It increases insulin synthesis and secretion while reducing glucagon release in a glucose-dependent manner. When blood glucose levels rise, Tirzepatid stimulates pancreatic β-cells to secrete insulin, promoting glucose uptake and utilization, thereby lowering blood glucose levels; simultaneously, it inhibits pancreatic α-cells from secreting glucagon, reducing hepatic glucose output, further lowering blood glucose levels, and effectively controlling fasting and postprandial blood glucose levels[1,3].

Other mechanisms of action:

Tirzepatid also promotes satiety, which may be related to activating GLP-1 receptors, acting on the central nervous system, and influencing appetite regulation centers, leading patients to reduce food intake and thereby aiding in weight loss. It also delays gastric emptying, prolonging the time food remains in the stomach and slowly entering the small intestine, thereby preventing rapid increases in blood glucose levels[1].

Figure 1 Mechanism of action of Tirzepatide [6].

What are the applications of Tirzepatide?

Treatment of type 2 metabolism:

Tirzepatid is approved for the treatment of adult patients with type 2 metabolism as an adjunct to diet and exercise. The SURPASS trial demonstrated that Tirzepatid significantly reduces hemoglobin A1c (HbA1c) levels, with reductions ranging from -1.87% to -2.59% (-20 to -28 mmol/mol). It also demonstrates superior glycemic control compared to certain GLP-1 receptor agonists, such as semaglutide 1 mg in the SUPRASS-2 trial. Additionally, it can reduce body weight, with weight loss ranging from -6.2 to -12.9 kg in clinical studies, which is particularly significant for patients with type 2 metabolism who often have overweight or obesity issues [1,4].

Obesity treatment:

Since Tirzepatid promotes satiety, reduces food intake, and promotes weight loss, it has potential therapeutic value for patients with obesity. Studies show that it can reduce weight by over 20%, improve patients' metabolic status, and serve as a new treatment option for obesity, helping obese patients lose weight and reduce the risk of various diseases associated with obesity[1,2].

Reduced risk of cardiovascular disease:

Patients with type 2 metabolism often face an increased risk of cardiovascular disease. In addition to lowering blood sugar and weight, Tirzepatid has positive effects on cardiovascular-related indicators, including reducing blood pressure, decreasing visceral fat accumulation, and lowering circulating triglyceride levels, thereby helping to reduce the risk of cardiovascular disease and improve patients' cardiovascular outcomes[4].

Potential treatment for non-alcoholic steatohepatitis (NASH):

Tirzepatid has potential therapeutic effects on NASH. By improving insulin sensitivity and regulating glucose and lipid metabolism, it can reduce hepatic steatosis and inflammation, offering a new direction for NASH treatment[5].

Conclusion

As a GIP/GLP-1 dual receptor agonist, Tirzepatid has demonstrated significant efficacy in the treatment of metabolism and metabolic disorders. By regulating insulin and glucagon secretion, delaying gastric emptying, and enhancing satiety, it effectively lowers hemoglobin A1c levels and reduces patient weight. Additionally, the drug improves cardiovascular risk factors such as lipid levels and blood pressure and demonstrates efficacy in non-alcoholic steatohepatitis.

About The Author

The above-mentioned materials are all researched, edited and compiled by Corevia Peptides.

Scientific Journal Author

De Block C is associated with the University of Antwerp and its related institutions in Belgium, including the Inflamed Ctr Excellence, University Hospital Antwerp (UZA and Univ Hosp Antwerp), and the Infla Med Ctr Excellence. His research spans several disciplines, such as Endocrinology & Metabolism, where he focuses on hormones and metabolic disorders; Gastroenterology & Hepatology, exploring digestive and liver diseases; General & Internal Medicine, addressing the diagnosis and management of common internal diseases; Nutrition & Dietetics, investigating nutrition and its health impacts; and Urology & Nephrology, studying the pathology and clinical practice of urinary and kidney diseases. He is a scholar with significant contributions to multiple medical fields. De Block C is listed in the reference of citation [4].

Relevant Citations

[1] Wong E, Cope R, Dima L, et al. Tirzepatid: A Dual Glucose-dependent Insulinotropic Polypeptide and  Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Metabolism Mellitus[J]. American Journal of Therapeutics, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, et al. An Overview on Tirzepatid, Dual-Targeted Treatment for Metabolism and Obesity[J]. International Journal of Innovative Research & Growth, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, et al. Tirzepatid a novel anti diabetic molecule unfold dual action[J]. Discover Public Health, 2024,21(1):75.DOI:10.1186/s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, et al. Tirzepatid for the treatment of adults with type 2 metabolism: An endocrine  perspective[J]. Metabolism Obesity & Metabolism, 2023,25(1):3-17.DOI:10.1111/dom.14831.

[5] Sood A, Kaur P, Syed O, et al. Revolutionizing metabolism care: unveiling Tirzepatid's potential in glycemic  control and beyond[J]. Expert Review of Clinical Pharmacology, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, et al. From a glycocentric approach in the patient with type 2 metabolism mellitus to a multi-organ prevention treatment and a decrease in the neuro-nephro-cardiovascular outcomes.[M]//2023.DOI: 10.5772/intechopen.1002363.